Program

Oral Sessions

Day 4, May 18（Fri.）　09:40-10:00　Room A (OrBit Hall)

4A-O1-P-0940　　PDF

Phosphoproteomics of non-small-cell lung cancer cells treated with erlotinib reveals drug-resistant signatures and potential targets

(NIBIOHN)
^oJun Adachi, Yuichi Abe, Maiko Nagano, Ayako Sato, Marina Kishida, Takeshi Tomonaga

Throughput and depth of mass spectrometry-based proteomics have been improved. We have developed a key technology on peptide separation for rapid and sensitive phosphoproteome analysis. Using these technologies, we compared temporal phosphoproteome and phosphotyrosine-proteome profiles of erlotinib-sensitive and resistant NSCLC cells treated by erlotinib for 0 h, 6 h and 24 h. We extracted active kinase and signaling candidates in resistant cells from phosphoproteome data and selected 46 inhibitors for drug screening. 24 of 46 inhibitors inhibited cell growth of at least one resistant cell line. Phosphoproteomic approach is applicable for the detection of the markers for drug-efficacy and the target candidates for overcoming drug resistance.